ArticleJournal for immunotherapy of cancer2026
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.
Milon de Jong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.